Pharma & Bio
- Korea's Biopharma Makes Its Case at BIO USA 2026
Korean drugmakers from SK Biopharm to DXVX used BIO USA 2026 to court partners across CDMO, clinical analytics and licensing pipelines.
- Korean Biotech's Four-Day Push at BIO USA 2026
Korean pharma and biotech firms used a packed four-day BIO USA 2026 schedule to court partners, from Kanaph Therapeutics to SK Biopharm and DXVX.